Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Afamelanotide→

Afamelanotide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
75921-69-6
Molecular formula
C78H111N21O19
Molecular weight
1646.8 g/mol
Drug class
Melanocortin-1 receptor (MC1R) agonistsynthetic alpha-melanocyte-stimulating-hormone analogue
Mechanism of action
Activates melanocortin-1 receptors on melanocytes, increasing eumelanin production and skin pigmentation. The additional eumelanin reduces penetration of light into the skin and helps reduce phototoxic reactions in erythropoietic protoporphyria.
Indications / reported uses
  • Prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP) under the EMA-authorised implant indication; specialist-centre use and product-specific monitoring apply

Sources: EMA EPAR — Scenesse (updated 7 Oct 2026) · EMA product information — Scenesse · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Afamelanotide Environmental Risk Assessment (ERA) (the Afamelanotide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.